Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369837 · ClinicalTrials.gov registry record · Phase 3
Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 131
- Enrollment target
NCT00369837 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 131 participants.
The verdict
NCT00369837, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 131 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the safety of clevidipine for treating severely elevated blood pressure, defined as systolic (SBP) \>180 mmHg and/or diastolic blood pressure (DBP) \>115 mmHg assessed on 2 successive occasions 15 minutes apart at baseline, in patients with or without major organ injury, particularly with respect to controlled dose adjustment to desired effect and prolonged continuous infusion. Enrollment of patients into the study was to continue until the target goal of 100 patients with at least 18 hours of continuous clevidipine treatment, including a minimum of 50 patients with acute or chronic end-organ injury, was met.
Interventions
- DRUG clevidipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369837
The ClinicalTrials.gov registry entry for NCT00369837 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which clevidipine is the first listed.
NCT00369837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369837 about?
NCT00369837 is a clinical study titled "Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)". The purpose of this study was to determine the safety of clevidipine for treating severely elevated blood pressure, defined as systolic (SBP) \>180 mmHg and/or diastolic blood pressure (DBP) \>115 mmHg assessed on 2 successive occasions 15 minutes apart at baseline, in patients with or without major...
What is the current status of trial NCT00369837?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 131 participants. The study started on 2006-09. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00369837?
The interventions under investigation include: clevidipine (DRUG).
Who is sponsoring clinical trial NCT00369837?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.